HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stephen Robb Selected Research

inclacumab

11/2016Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial.
5/2013Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stephen Robb Research Topics

Disease

3ST Elevation Myocardial Infarction
11/2016 - 07/2010
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2021
1Hypertension (High Blood Pressure)
01/2017
1Ovarian Neoplasms (Ovarian Cancer)
01/2017
1Proteinuria
01/2017
1Non-ST Elevated Myocardial Infarction
05/2013
1Infarction (Infarctions)
07/2010
1Heart Failure
06/2005

Drug/Important Bio-Agent (IBA)

2inclacumabIBA
11/2016 - 05/2013
2P-SelectinIBA
11/2016 - 05/2013
1Epithelial Cell Adhesion MoleculeIBA
01/2021
1protoporphyrin IXIBA
01/2021
1AcidsIBA
01/2021
1Bevacizumab (Avastin)FDA Link
01/2017
1Monoclonal AntibodiesIBA
11/2016
1GadoliniumIBA
07/2010
1Natriuretic PeptidesIBA
06/2005
1pro-brain natriuretic peptide (1-76)IBA
06/2005
1Brain Natriuretic Peptide (Natrecor)FDA Link
06/2005

Therapy/Procedure

3Percutaneous Coronary Intervention
11/2016 - 07/2010
1Therapeutics
01/2017